KT 253
Alternative Names: KT-253Latest Information Update: 06 Jun 2024
At a glance
- Originator Kymera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-mdm2 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Preclinical Haematological malignancies; Merkel cell carcinoma
Most Recent Events
- 03 Jun 2024 Efficacy and adverse events data from a phase I trial in haematological malignancies and solid tumours released by Kymera Therapeutics
- 23 May 2024 Updated pharmacodynamic, efficacy, and adverse event data from a phase I trial in Haematological malignancies and Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 02 Nov 2023 Pharmacokinetic, efficacy, and adverse event data from a phase I trial in Haematological malignancies and Solid tumours released by Kymera Therapeutics